Roche Holding AG (RHHVF)
| Previous close | 265.00 |
| Open | 266.95 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 266.95 - 277.43 |
| 52-week range | 252.87 - 334.30 |
| Volume | |
| Avg. volume | 1,966 |
| Market cap | 220.708B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 17.64 |
| EPS (TTM) | 15.65 |
| Earnings date | N/A |
| Forward dividend & yield | 10.25 (3.71%) |
| Ex-dividend date | 16 Mar 2023 |
| 1y target est | N/A |
GlobeNewswireRoche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
Elecsys® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory results and clinical information.The single test will inform clinicians if treatment is required and regimens are working in conjunction with other diagnostic assays.Almost 300 million people globally have chronic hepatitis B, causing a significant burden to health systems as it puts patients at high ri
Motley FoolIgnore Crypto: These Stocks Could Make You Rich
Investing in solid, growing businesses is a less risky road to riches than investing in Bitcoin or other cryptocurrencies.
Business WireGenentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development
SOUTH SAN FRANCISCO, Calif., November 21, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development. The collaboration is designed to significantly enhance Gene
